On September 15, 2021 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that the Company will host a virtual Investor Event on Monday, September 20, 2021 at 8:30 a.m. ET / 5:30 a.m. PT (Press release, Mirati, SEP 15, 2021, View Source [SID1234587757]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Company executives will discuss:
A top-line update from the Phase 2 registrational cohort of the KRYSTAL-1 study in previously-treated patients with KRASG12C-mutated non-small cell lung cancer (NSCLC)
Findings from the colorectal cancer (CRC) cohort of the Phase 1/2 KRYSTAL-1 study evaluating adagrasib as monotherapy and in combination with cetuximab in patients with heavily pretreated CRC harboring the KRASG12C mutation, as presented at the 2021 European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress
Results from the Phase 2 MRTX-500 study evaluating sitravatinib combined with nivolumab in patients with non-squamous NSCLC who progressed on or after prior checkpoint inhibitor therapy, to be presented at the 2021 ESMO (Free ESMO Whitepaper) Congress
Investors and the general public are invited to register and listen to a live webcast of the event through the "Investors and Media" section on Mirati.com. A replay of the event will be available shortly after the conclusion of the event.
Mirati studies at ESMO (Free ESMO Whitepaper) Congress 2021 include:
*All times noted are Central European Summer Time (CEST)
Presentation Title: KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab in Patients With Colorectal Cancer Harboring a KRASG12C Mutation
Author: Jared Weiss
Abstract Number: LBA6
Session: Presidential Symposium II
Presentation Date/Time: Sunday, September 19, 2021 at 15:47-16:02 CEST | Channel 1
Presentation Title: MRTX-500: Phase 2 Trial of Sitravatinib (Sitra) + Nivolumab (Nivo) in Patients (Pts) With Nonsquamous (NSQ) Non–Small-Cell Lung Cancer (NSCLC) Progressing on or After Prior Checkpoint Inhibitor (CPI) Therapy
Author: Ticiana A. Leal
Abstract Number: 1191O
Session: NSCLC Proffered Paper Session II
Presentation Date/Time: Monday, September 20, 2021 at 14:10-14:20 CEST | Channel 4